Compare Norfolk Southern Corporation (NSC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Novavax Inc — how do they compare? Norfolk Southern Corporation trades at $323.3 (market cap $72.62B), while Novavax Inc trades at $9.84 (market cap $1.62B). The key difference: Norfolk Southern Corporation is far larger — about 44.8× Novavax Inc's market cap, and Norfolk Southern Corporation pays a 1.67% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NSC | NVAX | |
|---|---|---|
Market Cap | $72.62B | $1.62B |
Sector | Technology | Health |
52-Week High | $352.98 | $11.19 |
52-Week Low | $272.36 | $6.22 |
Enterprise Value | $88.16B | $1.20B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $327.92, down 0.47% on the day, with technical indicators showing a bearish trend near key support at $327. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.52 surpassing estimates of $3.32, while profitability remains robust with a net income margin of 21.02%. A proposed merger with Union Pacific, under STB review, dominates recent news, alongside institutional buying interest.
NSC presents a mixed outlook: solid fundamentals and merger potential offer upside to the $369.67 consensus target, but regulatory hurdles and a bearish technical setup pose near-term risks. Investors should weigh the company's earnings momentum against integration uncertainties and market volatility.
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
